Abstract：
Growing clinical interest in psychedelic-assisted therapies has led to a second wave of research involving psilocybin, lysergic acid diethylamide (LSD), 3,4-methylenedioxymethamphetamine (MDMA) and other substances. Data suggests that these compounds have the potential to treat mental health conditions that are especially prevalent in older adults such as depression, anxiety, existential distress, and posttraumatic stress disorder.
The goal of this study was to quantify the prevalence of older adults enrolled in psychedelic clinical trials and explore safety data in this population.
A systematic review was conducted following the 2020 PRISMA guidelines. Search criteria included all trials published in English using psychedelic substances to treat psychiatric conditions, including addiction as well as existential distress related to serious illness. Articles were identified from literature searches on PubMed, EBSCO, and EMBASE.
4376 manuscripts were identified, of which 505 qualified for further review, with 36 eventually meeting eligibility criteria. Of the 1400 patients enrolled in the 36 studies, only 19 were identified as 65 or older, representing less than 1.4% of all trial participants. For 10 of these 19 older adults, detailed safety data was obtained. No serious adverse events (AEs) occurred in any older adults and only transient mild-to-moderate AEs related to anxiety, gastrointestinal upset, and hypertension were reported during the psychedelic dosing sessions.
While existing data in older adults is limited, it suggests that psychedelic-assisted psychotherapy can be safe and well tolerated in older adults. Therefore, psychedelic-assisted psychotherapy should be more rigorously investigated for the treatment of psychiatric conditions in this population.
The goal of this study was to quantify the prevalence of older adults enrolled in psychedelic clinical trials and explore safety data in this population.
A systematic review was conducted following the 2020 PRISMA guidelines. Search criteria included all trials published in English using psychedelic substances to treat psychiatric conditions, including addiction as well as existential distress related to serious illness. Articles were identified from literature searches on PubMed, EBSCO, and EMBASE.
4376 manuscripts were identified, of which 505 qualified for further review, with 36 eventually meeting eligibility criteria. Of the 1400 patients enrolled in the 36 studies, only 19 were identified as 65 or older, representing less than 1.4% of all trial participants. For 10 of these 19 older adults, detailed safety data was obtained. No serious adverse events (AEs) occurred in any older adults and only transient mild-to-moderate AEs related to anxiety, gastrointestinal upset, and hypertension were reported during the psychedelic dosing sessions.
While existing data in older adults is limited, it suggests that psychedelic-assisted psychotherapy can be safe and well tolerated in older adults. Therefore, psychedelic-assisted psychotherapy should be more rigorously investigated for the treatment of psychiatric conditions in this population.
摘要：
■对迷幻辅助疗法的临床兴趣不断增长，导致了涉及psilocybin的第二波研究，麦角酰二乙胺（LSD），3,4-亚甲二氧基甲基苯丙胺（MDMA）和其他物质。数据表明，这些化合物有可能治疗在老年人中特别普遍的心理健康状况，如抑郁症。焦虑,存在的痛苦，和创伤后应激障碍。
这项研究的目的是量化参加迷幻临床试验的老年人的患病率，并探索该人群的安全性数据。
■根据2020年PRISMA指南进行了系统评价。搜索标准包括所有以英文发表的使用迷幻药物治疗精神病的试验，包括成瘾以及与严重疾病相关的生存困扰。文章是从PubMed上的文献检索中确定的，EBSCO,和EMBASE。
■确定了4376份手稿，其中505人有资格进一步审查，36人最终符合资格标准。在这36项研究的1400名患者中，只有19人被确定为65岁或以上，占所有试验参与者的不到1.4%。对于这19名老年人中的10名，获得了详细的安全性数据.任何老年人均未发生严重不良事件（AE），仅发生与焦虑相关的短暂轻度至中度AE。肠胃不适,在迷幻药给药期间报告了高血压。
■虽然老年人的现有数据有限，这表明迷幻药辅助心理治疗在老年人中是安全且耐受性良好的.因此,应该更严格地研究迷幻辅助心理治疗对这一人群精神病的治疗。
这项研究的目的是量化参加迷幻临床试验的老年人的患病率，并探索该人群的安全性数据。
■根据2020年PRISMA指南进行了系统评价。搜索标准包括所有以英文发表的使用迷幻药物治疗精神病的试验，包括成瘾以及与严重疾病相关的生存困扰。文章是从PubMed上的文献检索中确定的，EBSCO,和EMBASE。
■确定了4376份手稿，其中505人有资格进一步审查，36人最终符合资格标准。在这36项研究的1400名患者中，只有19人被确定为65岁或以上，占所有试验参与者的不到1.4%。对于这19名老年人中的10名，获得了详细的安全性数据.任何老年人均未发生严重不良事件（AE），仅发生与焦虑相关的短暂轻度至中度AE。肠胃不适,在迷幻药给药期间报告了高血压。
■虽然老年人的现有数据有限，这表明迷幻药辅助心理治疗在老年人中是安全且耐受性良好的.因此,应该更严格地研究迷幻辅助心理治疗对这一人群精神病的治疗。
